- Ongoing, recruitingTherapeutic exploratory (Phase II)
(14308) Randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonary hypertension associated with left ventricular systolic dysfunction.
This study is looking at a new medicine called Riociguat for people with high blood pressure in the lungs due to a weak heart. It aims to see if the drug can lower this pressure and improve heart function, comparing it to a dummy pill.
For: Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)Italy · Czechia · Germany - Ongoing, recruitingTherapeutic use (Phase IV)
An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
This study looks at how a medicine called Riociguat affects the right side of the heart in people with pulmonary hypertension. Researchers want to see if it changes the size and function of the heart's right chambers over 24 weeks.
For: Chronic Thromboembolic Pulmonary Hypertension · Pulmonary Arterial HypertensionGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension Double-blind, randomized, multicenter, multinational, placebo-controlled phase IIa study
This study is testing a new medicine called riociguat for a condition where blood vessels in the lungs become narrow. Researchers want to see if the medicine can help improve blood flow and if it's safe for people with early signs of this lung condition.
For: Pulmonary vascular diseaseFrance · Germany · Austria